Candida Albicans
| Morphology | Fungus belonging to the Candiaceae family. Polymorphic fungus as it can occur as yeast
                                                         or pseudohyphal forms. | 
|---|---|
| Disease | Opportunistic commensal pathogen causing candidiasis such as thrush (oral), vaginal infections, superficial infection of mucous membranes, eye infections, macerated skin infections. | 
| Zoonosis | None. | 
| Host Range | Humans. | 
|---|---|
| Modes of Transmission | Most infections result from the patient’s own flora, rather than from cross infection.
                                                                            | 
| Signs and Symptoms | Most frequent clinical form is thrush/oral candidiasis and is characterized by white
                                                                     patches.  | 
| Infectious Dose | Unknown. | 
| Incubation Period | Unknown. | 
| Prophylaxis | None. | 
|---|---|
| Vaccines | None. | 
| Treatment | Amphotericin B, nystatin, flucytosine, the azoles, echinocandins | 
| Surveillance | Monitor for symptoms. | 
| MSU Requirements | Report any exposures | 
| Laboratory Acquired Infections (LAIs) | Low risk of infection. A medical student has been reported to have developed a rash
                                                         and folliculitis 2 days after she spilled a heavy suspension of C. albicans on her
                                                         leg while conducting a laboratory experiment. | 
|---|---|
| Sources | Epithelial scrapings or exudates from lesions, sputum, bronchoalveolar lavage, and
                                                                     blood. Cultures, frozen stocks, other samples described in IBC protocol. | 
| Canadian PSDS: | https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/candida-albicans-pathogen-safety-data-sheet.html | 
|---|---|
| BMBL | https://www.cdc.gov/labs/BMBL.html | 
| NIH Guidelines | 
| Risk Group 2 | Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available. | 
|---|---|
| BSL2 | For all procedures involving suspected or known infectious specimen or cultures. | 
| ABSL2 | For all procedures utilizing infected animals. | 
| Small | Notify others working in the lab. Remove PPE and don new PPE. Cover area of the spill
                                                   with absorbent material and add fresh 1:10 bleach:water. Allow 20 munutes (or as directed)
                                                   of contact time. After 20 minutes, cleanup and dispose of materials. | 
|---|---|
| Large | 
 | 
| Mucous membrane  | Flush eyes, mouth, or nose for 5 minutes at eyewash station. | 
|---|---|
| Other Exposures  | Wash area with soap and water for 5 minutes.  | 
| Reporting | Immediately report incident to supervisor, complete a First Report of Injury form, and submit to Safety and Risk Management. | 
| Medical Follow-up  | During business hours: Bridger Occupational Health 3406 Laramie Drive. Weekdays 8am -6pm.  Weekends 9am-5pm After business hours: Bozeman Deaconess Hospital Emergency Room 915 Highland Blvd Bozeman, MT | 
| Disinfection | Susceptible to 1:10 bleach:water, 70 % ethanol, and 4 % potassium iodide, accelerated
                                                            hydrogen peroxide | 
|---|---|
| Inactivation | Inactivated by moist heat (1 hour at 121oC). | 
| Survival Outside Host | Can survive on inanimate surfaces for 24 hours to 120 days, and on palms for about
                                                                        45 minutes. | 
| Minimum PPE Requirements | Lab coat, disposable gloves, safety glasses, closed toed shoes, long pants | 
|---|---|
| Additional Precautions | Additioanl PPE may be required depending on lab specific SOPs and IBC Protocol. | 
